What we do Shukra Pharmaceuticals Ltd manufactures and trades pharmaceutical formulations and provides laboratory testing services, serving major pharma companies in India. |
Founded in 1,993 |
Market share Operates in pharmaceutical formulations with major clients like Cadila and Intas; niche player with WHO-GMP certification. |
Problem solved Addresses the need for a wide range of quality pharmaceutical products, including antibiotics and specialty medicines, plus lab testing support. |
Top clients or who we serve B2B; key clients include Cadila Healthcare, Intas Pharmaceuticals, and Makers Laboratories. |
Key management Dakshesh Shah (Managing Director) leads a robust board with independent and executive directors. |
Our journey and innovations Founded 1993; renamed in 2016; WHO-GMP certified; partnered for robotic surgery projects in 2025. |
Where we operate Primarily India, manufacturing in Gujarat and serving pharmaceutical companies domestically and globally. |
Top products or what we offer Antibiotics (Penicillin, Cephalosporin), antivirals, vitamins, analgesics, and other pharma formulations. |
Top brands - |
Raw materials needed Pharmaceutical active ingredients and excipients for drug formulation. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue mainly recurring from pharmaceutical manufacturing and contract lab services. |
Our industry position Established with notable clients; competitive in formulation manufacturing and certifications with growth potential. |
Financial highlights FY 2024-25 revenue Rs. 3258.73 Lacs; PAT Rs. 957.52 Lacs; profit before tax Rs. 1333.66 Lacs. |
Geographical revenue split - |
Order book - |
Whats driving growth Increasing demand for pharmaceuticals, regulatory approvals, new collaborations, and product diversification. |
Our future plans Expand manufacturing capacity, enhance product portfolio, and leverage partnerships for advanced healthcare tech. |
Our green promise - |
Our people and values Maintains a committed workforce with focus on governance, ethics, and inclusive workplace. |
Key challenges ahead Regulatory compliance, market competition, and supply chain dependencies. |
Interesting facts Successfully executed a 3:1 bonus share issue in 2024; WHO-GMP certification secured. |
Risks and strategy Mitigates regulatory and operational risks through internal audits, governance, and compliance frameworks. |
